Market Research Report
Glycoprotein 41 (gp41) - Drugs in Development, 2021
|Glycoprotein 41 (gp41) - Drugs in Development, 2021|
Published: September 30, 2021
Global Markets Direct
Content info: 67 Pages
Delivery time: 1-2 business days
According to the recently published report 'Glycoprotein 41 - Drugs In Development, 2021'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.
The report 'Glycoprotein 41 - Drugs In Development, 2021' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.